Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib
详细信息 查看全文
- 作者：Martina Tilioa ; 1 ; Valentina Gambinia ; 1 ; Junbiao Wanga ; 1 ; Chiara Garullia ; Cristina Kalogrisa ; Cristina Andreania ; Caterina Bartolaccia ; Maria Elexpuru Zabaletaa ; Lucia Pietrellaa ; Albana Hysib ; Manuela Iezzib ; Barbara Bellettic ; Fiorenza Orlandod ; Mauro Provincialid ; Roberta Galeazzie ; Cristina Marchinia ; 1 ; cristina.marchini@unicam.it" class="auth_mail" title="E-mail the corresponding author ; Augusto Amicia ; 1 ; augusto.amici@unicam.it" class="auth_mail" title="E-mail the corresponding author
- 关键词：HER2 isoform ; Breast cancer ; Δ16HER2 mice ; Targeted therapies ; Drug resistances
- 刊名：Cancer Letters
- 出版年：2016
- 出版时间：10 October 2016
- 年：2016
- 卷：381
- 期：1
- 页码：76-84
- 全文大小：3112 K
文摘
- •
Saracatinib and Dacomitinib block the oncogenic Δ16HER2/Src axis in vitro.
- •
Erk signaling escape pathway mediates acquired resistance to Saracatinib in vivo.
- •
Δ16HER2+ breast tumors are refractory to reversible TKI Lapatinib.
- •
Δ16HER2+ breast tumors are responsive to irreversible TKI Dacomitinib.